Against the background of the global incidence of respiratory diseases continuing to rise and the demand for home medical care becoming normalized, the safety, stability and accuracy of atomizer tablets, the core component of respiratory medical equipment such as nebulizers and ventilators, have become critical to patients' lives and health. Shenzhen Liandaqi Precision Ceramics Co., Ltd. (hereinafter referred to as "Liandaqi"), which has been deeply involved in the field of medical precision components for nearly 10 years, has recently officially launched a series of medical-grade atomizer tablets that meet international medical standards. With strict production control and breakthrough technology, it provides global respiratory medical equipment companies with core component solutions that combine clinical reliability and compliance.
According to the "2025 Global Respiratory Medical Equipment Market Report", the global medical nebulizer market will reach US$12.6 billion in 2024, of which sales of household medical nebulizers will increase by 41% year-on-year. Different from ordinary civilian atomization components, medical atomization tablets are directly involved in the drug delivery process. The size of the atomized particles, material safety, anti-pollution capabilities and other indicators directly affect the drug absorption efficiency and patient medication safety. "Traditional atomized tablets often have a material that is not corrosion-resistant and atomized particles are uneven, resulting in a drug waste rate of up to 30% and even the risk of cross-infection." Dr. Zhang, director of the Medical Division of Mericon, emphasized that this industry pain point is the core driving force for companies to develop medical-grade atomized tablets.
The medical-grade atomizer tablets launched by Liandaqi this time fully cover mainstream nebulizer types such as compression and ultrasonic nebulizers, and are suitable for children's special nebulizers, portable ventilators, intensive care unit (ICU) special atomization equipment and other scenarios. The core advantages are reflected in the four dimensions of "compliance certification, material safety, precise atomization, long-term stability", and are fully in line with the world's top medical certification standards such as EU CE MDR, US FDA 21 CFR 820 and China NMPA.
In terms of compliance, Liandaqi has established a full-process medical-grade quality control system from raw material procurement to finished product delivery. Each batch of raw materials must provide a third-party testing report, and key indicators can be traced back to the source; the production workshop strictly follows the 10,000-level clean workshop standard, and staff must undergo double disinfection and aseptic operation training before they can work. The product has passed ISO 13485 medical device quality management system certification. Each atomized tablet comes with a unique traceability code, which allows real-time query of production batches, testing data and other information, providing complete compliance support for downstream equipment companies.
Material safety is the core bottom line of medical atomizer tablets. Liandaqi abandons traditional industrial-grade ceramic materials and uses medical-grade 99.8% high-purity alumina ceramics as the base. This material has been verified by biocompatibility tests to be non-cytotoxic and non-allergenic, and has no chemical precipitation after contact with common aerosolized drugs such as physiological saline and antibiotics. In response to the problem of drug residues, the R&D team innovatively uses "amphiphobic coating technology" to form a micron-level hydrophobic and oleophobic film on the ceramic surface. This not only reduces cross-contamination caused by drug adhesion, but also increases cleaning efficiency by 60%. It is especially suitable for medical institutions where multiple patients are used.
Precise atomization directly determines the treatment effect. Through the optimization of piezoelectric ceramic formula and precise control of vibration frequency, Liandaqi stably controls the diameter of atomized particles within the "golden treatment range" of 1-5 microns - particles in this range can be accurately deposited in the small airways and alveoli of the lungs, increasing the drug absorption efficiency to more than 85%, which is much higher than the average level of 60% of traditional atomized tablets. For different treatment needs, the product provides two core frequency specifications of 1.7MHz and 2.4MHz: the 1.7MHz model is suitable for children's atomizers, and the atomization volume is gentle and controllable to avoid irritating the respiratory tract; the 2.4MHz model is used for severe adult treatment, and the atomization volume can reach 0.5-1.2ml/min, meeting the needs of large-dose drug delivery.
Long-term stability is the core demand of medical institutions and patients. Liandaqi adopts the dual process of "vacuum sintering + precision polishing" to increase the vibration fatigue life of the atomizer to more than 20,000 hours, which is equivalent to 13 years of continuous service with 4 hours of daily use, far exceeding the industry average standard of 10,000 hours. In the stability test, the frequency fluctuation error of this atomizing tablet was controlled within ±0.02MHz at ambient temperatures from -10°C to 60°C. After 5,000 hot and cold cycle tests, the atomization volume attenuation rate was only 3%, fully adapting to the long-term use needs of medical equipment.
With excellent product performance, Liandaqi medical-grade atomizer tablets have been successfully used in medical scenarios in more than 30 countries and regions around the world. A German household medical equipment brand previously failed to pass CE MDR certification for its children's nebulizer in the European market due to "low drug delivery efficiency" due to insufficient accuracy of atomizer tablets. After cooperating with Liandaqi, the upgraded product using its medical-grade atomizer tablets not only successfully passed the certification, but also became a recommended product for European pediatric hospitals due to its advantages of "fine atomization and less than 25 decibels of noise", with sales exceeding 500,000 units in the first half of the year. The head of R&D of the brand said: "Liandaqi's atomized tablets not only meet medical compliance requirements, but also enhance the clinical value of the product through technological optimization. This is the key to our long-term cooperation."
In order to better serve global medical equipment companies, Liandaqi has established a professional technical support and after-sales service system. In response to the individual needs of customers, we provide "customized parameter adjustment" services, which can optimize the performance of atomized tablets according to equipment power, liquid type and other needs; equipped with a medical technical team of 20 people, we provide free product adaptation guidance and compliance consultation to assist customers in completing the preparation of medical certification materials. In terms of after-sales service, three regional service centers have been established in Germany, the United States, and India to provide 7×24-hour technical response to ensure that the production and after-sales needs of medical equipment companies can be quickly resolved.
Facing the trend of "miniaturization and intelligence" in respiratory medical equipment, Liandaqi has launched the research and development of the next generation of intelligent medical atomization tablets. It plans to integrate pressure sensing and data transmission functions to achieve real-time monitoring of the atomization process and accurate dose statistics, and provide data support for telemedicine. At present, 5 international patents have been applied for related technologies, and mass production is expected to be achieved in the second half of 2026.
As a professional supplier in the field of medical aerosol tablets, Liandaqi always takes "medical grade standards" as its core and uses technological innovation to protect patients' health. If your company is seeking safe and reliable core component solutions for nebulizers and respiratory equipment, please contact us in the following ways: send an email to yunying@liandaqi.com to obtain a complete product certification report and samples; communicate in real time with a medical product specialist via WhatsApp (+86 18682283578); visit the official website https://www.liandaqi.net/ to view clinical test data and cooperation cases. Liandaqi looks forward to joining hands with global medical equipment companies to build a line of defense for respiratory health protection.